Metformin (anti-diabetic), somatostatin (statin), and mifepristone (anti-progestogen) increase the disease-free survival of patients suffering from ccRCC compared to the approved first-line treatment [20,21], shown by a retrospective analysis of a clinical evaluation in ccRCC. Here, SST is linked to nonpapillary renal cell carcinoma.